Lapatinib tablets had a market value of approximately $61 million, according to IQVIA June 2020 data. Lupin’s second new entry is fosaprepitant for injection, 150 mg single-dose vial.

March 13, 2007, was an exciting day for women with HER2–positive breast cancer. This was the day the FDA approved a novel compound, lapatinib, for patients with HER2–positive advanced or ...

In an updated analysis of the PHOEBE trial, 66.6% of patients treated with pyrotinib plus capecitabine were alive after 2 years compared with 58.8% of those on lapatinib-capecitabine (HR 0.69, 95% ...

However, the label for lapatinib 1 (approved by the US Food and Drug Administration on March 13, 2007) includes a number of pharmacokinetic details of high interest to both prescribers and patients. A ...

The low-fat breakfast produced mean increases in lapatinib area under the concentration-time curve (AUC) of 167% (2.67-fold) and maximum concentration (C max) of 142% (2.42-fold).The high-fat ...

In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo ...

Lapatinib reduces the number of large brain metastases in a mouse model of metastatic breast cancer, relative to untreated mice, researchers report. Share: Facebook Twitter Pinterest LinkedIN Email ...

Lapatinib doubled the time to progression when added to capecitabine in advanced HER2-positive breast cancer that had progressed after chemotherapy and trastuzumab. This trial, halted early ...

Lapatinib could be used to treat inflammatory breast cancer, an aggressive from of the disease which represents up to one tenth of malignant breast cancer cases. The findings of this phase II ...

Lapatinib is administered orally at a dosage of 1,500 mg (6 tablets) per day. The net price per pack of 84 tablets is £965.16 (excluding VAT; BNF, edition 62). The acquisition cost for a lifetime of ...

There are few treatment options for patients with metastatic HER2-positive breast cancer who are unresponsive to trastuzumab. The combination of lapatinib and capecitabine significantly prolongs ...